Response to Re-challenge of a MEK Inhibitor in a Patient with Recurrent Low-grade Serous Carcinoma of the Peritoneum

Overview

Journal Gynecol Oncol Rep

Publisher Elsevier

Date 2020 Nov 18

PMID 33204798

Authors

David M Gershenson

Priya Bhosale

Rachel N Grisham

Affiliations

Soon will be listed here.

Abstract

Low-grade serous carcinoma of the ovary/peritoneum is a rare epithelial cancer subtype characterized by younger age at diagnosis, relative chemoresistance, and prolonged overall survival compared with high-grade serous carcinoma. In addition, alterations in the mitogen activated protein kinase pathway are frequent and play a major role in the pathogenesis of this tumor. MEK inhibitors have demonstrated promising activity in the treatment of recurrent low-grade serous carcinoma. Although prevailing wisdom in cancer therapy is that the re-treatment with a drug after emergence of resistance is futile, we report the initial case of a patient with recurrent low-grade serous carcinoma who experienced a partial response when re-challenged with a MEK inhibitor after previously having prolonged stable disease followed by disease progression on a MEK inhibitor.

References

Malpica A, Deavers M, Lu K, Bodurka D, Atkinson E, Gershenson D . Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004; 28(4):496-504. DOI: 10.1097/00000478-200404000-00009. View

Takekuma M, Wong K, Coleman R . A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib. Gynecol Oncol Res Pract. 2016; 3:5. PMC: 4880811. DOI: 10.1186/s40661-016-0026-5. View

Kemper K, de Goeje P, Peeper D, van Amerongen R . Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy. Cancer Res. 2014; 74(21):5937-41. DOI: 10.1158/0008-5472.CAN-14-1174. View

Kozar I, Margue C, Rothengatter S, Haan C, Kreis S . Many ways to resistance: How melanoma cells evade targeted therapies. Biochim Biophys Acta Rev Cancer. 2019; 1871(2):313-322. DOI: 10.1016/j.bbcan.2019.02.002. View

Dai B, Meng J, Peyton M, Girard L, Bornmann W, Ji L . STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 2011; 71(10):3658-68. PMC: 3392199. DOI: 10.1158/0008-5472.CAN-10-3647. View

Balmanno K, Chell S, Gillings A, Hayat S, Cook S . Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer. 2009; 125(10):2332-41. DOI: 10.1002/ijc.24604. View

Mandal R, Becker S, Strebhardt K . Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene. 2015; 35(20):2547-61. DOI: 10.1038/onc.2015.329. View

Valpione S, Carlino M, Mangana J, Mooradian M, McArthur G, Schadendorf D . Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. Eur J Cancer. 2018; 91:116-124. DOI: 10.1016/j.ejca.2017.12.007. View

Fernandez M, DiMattia G, Dawson A, Bamford S, Anderson S, Hennessy B . Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. Am J Cancer Res. 2016; 6(10):2235-2251. PMC: 5088288. View

10.

Grisham R, Sylvester B, Won H, McDermott G, DeLair D, Ramirez R . Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. J Clin Oncol. 2015; 33(34):4099-105. PMC: 4669594. DOI: 10.1200/JCO.2015.62.4726. View

11.

Monk B, Grisham R, Banerjee S, Kalbacher E, Mirza M, Romero I . MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020; 38(32):3753-3762. PMC: 7655017. DOI: 10.1200/JCO.20.01164. View

12.

Slomovitz B, Gourley C, Carey M, Malpica A, Shih I, Huntsman D . Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020; 156(3):715-725. DOI: 10.1016/j.ygyno.2019.12.033. View

13.

Farley J, Brady W, Vathipadiekal V, Lankes H, Coleman R, Morgan M . Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2012; 14(2):134-40. PMC: 3627419. DOI: 10.1016/S1470-2045(12)70572-7. View